KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other financing activities (2016 - 2023)

Travere Therapeutics' Other financing activities history spans 9 years, with the latest figure at -$259000.0 for Q4 2023.

  • For Q4 2023, Other financing activities fell 102.2% year-over-year to -$259000.0; the TTM value through Sep 2024 reached -$259000.0, down 102.44%, while the annual FY2023 figure was -$1.4 million, 113.99% down from the prior year.
  • Other financing activities reached -$259000.0 in Q4 2023 per TVTX's latest filing, roughly flat from -$260000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $11.8 million in Q4 2022 to a low of -$11.8 million in Q3 2022.
  • Average Other financing activities over 3 years is $1.0 million, with a median of -$259000.0 recorded in 2023.
  • The largest YoY upside for Other financing activities was 97.79% in 2023 against a maximum downside of 165.74% in 2023.
  • A 3-year view of Other financing activities shows it stood at $772000.0 in 2019, then soared by 1422.93% to $11.8 million in 2022, then plummeted by 102.2% to -$259000.0 in 2023.
  • Per Business Quant, the three most recent readings for TVTX's Other financing activities are -$259000.0 (Q4 2023), -$260000.0 (Q3 2023), and -$259000.0 (Q2 2023).